{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:22:43Z","timestamp":1791318163395,"version":"4.3.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2007,5,22]],"date-time":"2007-05-22T00:00:00Z","timestamp":1179792000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2007,8,21]]},"DOI":"10.1007\/s00198-007-0367-3","type":"journal-article","created":{"date-parts":[[2007,5,21]],"date-time":"2007-05-21T19:36:41Z","timestamp":1179776201000},"page":"1211-1218","source":"Crossref","is-referenced-by-count":50,"title":["Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis"],"prefix":"10.1007","volume":"18","author":[{"given":"J. P.","family":"Devogelaer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Burckhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. J.","family":"Meunier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Goemaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Lippuner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Body","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Samsioe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Felsenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Fashola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Sanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. E.","family":"Ortmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Trechsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Krasnow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. F.","family":"Eriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Garnero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,5,22]]},"reference":[{"key":"367_CR1","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","volume":"75","author":"DD Mellstr\u00f6m","year":"2004","unstructured":"Mellstr\u00f6m DD, S\u00f6rensen OH, Goemaere S et al (2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75:462\u2013468","journal-title":"Calcif Tissue Int"},{"key":"367_CR2","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer JP et al (2004) Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women. Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 350:1189\u20131199","journal-title":"N Engl J Med"},{"key":"367_CR3","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","volume":"346","author":"IR Reid","year":"2002","unstructured":"Reid IR, Brown JP, Burckhardt P et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653\u2013661","journal-title":"N Engl J Med"},{"key":"367_CR4","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1359\/jbmr.2000.15.8.1526","volume":"15","author":"P Garnero","year":"2000","unstructured":"Garnero P, Sornay-Rendu E, Claustrat B et al (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res 15:1526\u20131536","journal-title":"J Bone Miner Res"},{"issue":"14","key":"367_CR5","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 282(14):1344\u20131352, Oct 13","journal-title":"JAMA"},{"key":"367_CR6","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","volume":"19","author":"DC Bauer","year":"2004","unstructured":"Bauer DC, Black DM, Garnero P et al (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. Fracture Intervention Trial Study Group. J Bone Miner Res 19:1250\u20131258","journal-title":"J Bone Miner Res"},{"key":"367_CR7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31\u201341","journal-title":"Nephron"},{"key":"367_CR8","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bone.2004.01.008","volume":"34","author":"R Recker","year":"2004","unstructured":"Recker R, Stakkestad JA, Chesnut CH et al (2004) Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34:890\u2013899","journal-title":"Bone"},{"key":"367_CR9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s001980170126","volume":"12","author":"JY Reginster","year":"2001","unstructured":"Reginster JY, Christiansen C, Roux C et al (2001) Intermittent cyclic tiludronate in the treatment of osteoporosis. Osteoporosis Int 12:169\u2013177","journal-title":"Osteoporosis Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-007-0367-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-007-0367-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-007-0367-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T19:00:49Z","timestamp":1558638049000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-007-0367-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,22]]},"references-count":9,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,8,21]]}},"alternative-id":["367"],"URL":"https:\/\/doi.org\/10.1007\/s00198-007-0367-3","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,22]]}}}